• PHP40 EFFECTS OF EDUCATIONAL INTERVENTION ON PRESCRIPTION WRITING IN PUBLIC AND PRIVATE HOSPITALS IN BENIN CITY, NIGERIA

    May 1, 2007, 00:00

  • PCN5 PHARMACOECONOMIC ANALYSIS OF SORAFENIB AND SUNITINIB FOR FIRST LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC) COMPARED WITH COMBINATION THERAPY OF BEVACIZUMAB, GEMCITABINE, AND CAPECITABINE (BGC) AT A LARGE CANCER CENTER

    May 1, 2007, 00:00

  • PCN54 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH AXITINIB (AG-013736)

    May 1, 2007, 00:00

  • PCV61 DIFFERENCES IN ANTIBIOTICS PRESCRIBED BY PHYSICIANS WITH HIGH AND LOW INFECTION RATES APPLIED TO PATIENTS UNDERGOING CARDIOVASCULAR SURGERY

    May 1, 2007, 00:00

  • PAA25 IMPACT OF ALLERGIC RHINITIS ON WORK PRODUCTIVITY

    May 1, 2007, 00:00

  • PR2 PREDICTING DISEASE BURDEN IN EQ-5D US UNITS FROM SEVEN OTHER MEASUREMENT SYSTEMS (EQ-5D UK, HALEX, HUI MARK 2, HUI MARK 3, QWB-SA, SF-6D(12), SF-6D(36))

    May 1, 2007, 00:00

  • PHM1 A COMPARISON OF INPATIENT OUTCOMES BETWEEN SICKLE CELL DISEASE AND NON-SICKLE CELL DISEASE PATIENTS UNDERGOING HIGH-VOLUME SURGICAL PROCEDURES

    May 1, 2007, 00:00

  • PDB20 COMPARISON OF ROSIGLITAZONE VERSUS PIOGLITAZONE INTRODUCTION AND ASSOCIATED HEALTH CARE UTILIZATION IN TYPE 2 DIABETES MEDICAID ENROLLEES

    May 1, 2007, 00:00

  • PND27 DETECTION OF DIFFERENTIAL ITEM FUNCTIONING BETWEEN ENGLISH AND CHINESE VERSIONS OF THE PDQ-8

    May 1, 2007, 00:00

  • PRS6 EVALUATING THE COST-EFFECTIVENESS OF TIOTROPIUM IN THE TREATMENT OF MODERATE CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    May 1, 2007, 00:00

  • PUK11 MEDICAL AND WORK PRODUCTIVITY COSTS BEFORE AND AFTER DIAGNOSIS OF ANEMIA IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) PATIENTS

    May 1, 2007, 00:00

  • MH2 COMPARISON OF HEALTH CARE COSTS AND HOSPITALIZATION DAYS OF ELDERLY MAJOR DEPRESSIVE DISORDER PATIENTS TREATED WITH ESCITALOPRAM AND OTHER ANTIDEPRESSANTS

    May 1, 2007, 00:00

  • PHM8 ESTIMATING UTILITY VALUES FOR SELF-REPORTED JOINT PAIN AND MOTION LIMITATION OUTCOMES IN ADULT HEMOPHILIA PATIENTS-THE HEMOPHILIA UTILIZATION GROUP STUDY-PART V (HUGS-V)

    May 1, 2007, 00:00

  • PEY8 EFFECTIVENESS AND COSTS OF BETA-BLOCKERS WITH CAI OR ALPHA-2 FOLLOWING GLAUCOMA TREATMENT FAILURE- AN ANALYSIS CONDUCTED ON THE UK GENERAL PRACTITIONER RESEARCH DATABASE

    May 1, 2007, 00:00

  • PMC27 EFFECT OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) ON THE HEALTH SERVICE UTILIZATION FOR PATIENTS WITH CHRONIC DISEASES

    May 1, 2007, 00:00

  • PMH30 HEALTH CARE BURDEN OF PATIENTS WITH ALCOHOL DEPENDENCE SYNDROME

    May 1, 2007, 00:00

  • AO4 ADHERENCE TO GASTROPROTECTION AND THE RISK OF NSAID-RELATED UPPER GASTROINTESTINAL COMPLICATIONS

    May 1, 2007, 00:00

  • PCN55 TRANSLATION AND CULTURAL ADAPTATION OF HEALTH UTILITIES INDEX (HUI) FOR ASSESSING EFFECTS OF NEUTROPENIA AMONG PEDIATRIC ONCOLOGY PATIENTS IN TURKEY

    May 1, 2007, 00:00

  • PMC8 CREATING KNOWLEDGE ABOUT ADVERSE DRUG REACTIONS-A CRITICAL ANALYSIS OF THE DANISH REPORTING SYSTEM FROM 1968 TO 2005

    May 1, 2007, 00:00

  • PCV9 ISOLATED SYSTOLIC HYPERTENSION IN A COHORT OF INNER CITY MINORITY PATIENTS

    May 1, 2007, 00:00

  • MH1 OUTCOMES ASSOCIATED WITH THE IMPLEMENTATION OF A DOSE OPTIMIZATION PROGRAM FOR ATYPICAL ANTIPSYCHOTIC MEDICATIONS IN A MANAGED CARE ORGANIZATION

    May 1, 2007, 00:00

  • PIN36 MICROSIMULATION OR COHORT MODELING? A COMPARATIVE CASE STUDY IN HIV INFECTION

    May 1, 2007, 00:00

  • PHP35 BREAK-EVEN COST ANALYSIS OF MEDICATION THERAPY MANAGEMENT PROGRAMS FOCUSING ON ADVERSE DRUG EVENT PREVENTION

    May 1, 2007, 00:00

  • PMH48 PREFERENCE AND WILLINGNESS-TO-PAY STUDY TO ASSESS THE VALUE OF ATOMOXETINE USING DISCRETE CHOICE ANALYSIS- UK PARENTS PERSPECTIVE

    May 1, 2007, 00:00

  • PMC22 TRADING HEALTH VALUES IN CHILE AND THE US USING EQ-5D

    May 1, 2007, 00:00

  • PIN13 COST-EFFECTIVENESS OF LINEZOLID IN GRAM-POSITIVE INFECTIONS- CONSISTENCY OF ECONOMIC ADVANTAGE FROM MULTIPLE HEALTH CARE SYSTEMS

    May 1, 2007, 00:00

  • PCV3 HYPERTENSION MAY NOT INFLUENCE CARDIOVASCULAR BENEFITS OF STATIN THERAPY. RESULTS FROM A METAREGRESSION ANALYSIS OF 69,984 PATIENTS

    May 1, 2007, 00:00

  • PDB6 RACIAL DIFFERENCES IN HOSPITALIZATIONS ASSOCIATED WITH MEDICATION USE IN MEDICAID ENROLLEES WITH TYPE 2 DIABETES

    May 1, 2007, 00:00

  • PHP26 MORE POLICY INITIATIVES IN THE AUSTRALIAN NATIONAL REIMBURSEMENT SYSTEM THAT WILL REDUCED COSTS DRAMATICALLY

    May 1, 2007, 00:00

  • PMC30 GUIDELINES FOR BUDGET IMPACT ANALYSIS IN CANADA

    May 1, 2007, 00:00

  • PAA3 EVALUATION OF RISK FACTORS AND PREDICTORS OF HEALTH OUTCOMES AMONG PERSONS WITH ASTHMA

    May 1, 2007, 00:00

  • PHM2 STUDY OF ANEMIA IN LONG-TERM CARE (SALT)- RELATIONSHIP BETWEEN ANEMIA AND FALLS IN THE NURSING HOME SETTING

    May 1, 2007, 00:00

  • PCN45 A PRACTICAL AND USEFUL COMBINATION OF MEASURES FOR ASSESSING THE COST-UTILITY OF TWO MAJOR TREATMENT STRATEGIES FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN CHILDHOOD- RESOURCE INTENSITY WEIGHTS (RIWS) AND THE HEALTH UTILITIES INDEX (HUI ...

    May 1, 2007, 00:00

  • PST4 COST-EFFECTIVENESS OF RECOMBINANT ACTIVATED FACTOR VII IN THE TREATMENT OF INTRACEREBRAL HEMORRHAGE OVER A TWO-YEAR MANAGED CARE ENROLLMENT PERIOD

    May 1, 2007, 00:00

  • PIN39 CULTURAL ADAPTATION AND VALIDATION OF A HEALTHRELATED QUALITY OF LIFE QUESTIONNAIRE (HRQOL) FOR ENGLISH-SPEAKING HEPATITIS B PATIENTS IN SINGAPORE

    May 1, 2007, 00:00

  • PCN26 FIRST-, SECOND- AND THIRD-LINE CHEMOTHERAPY FOR NONSMALL CELL LUNG CANCER- PATTERNS OF CARE AND COST

    May 1, 2007, 00:00

  • PPN12 PETS, PEOPLE AND DEMAND FOR ETODOLAC IN THE UNITED STATES OF AMERICA

    May 1, 2007, 00:00

  • PHP37 THE MARKET SHARE OF PRIVATE FOR-PROFIT AND NONPROFIT HEALTH CARE PROVIDERS FROM THE HUNGARIAN HEALTH INSURANCE BUDGET

    May 1, 2007, 00:00

  • OB2 THE COST OF THE METABOLIC SYNDROME IN THE ELDERLY- FINDINGS FROM THE CARDIOVASCULAR HEALTH STUDY

    May 1, 2007, 00:00

  • PMH3 ANTIDEPRESSANT PROPHYLAXIS FOR POST-STROKE DEPRESSION-A META-ANALYSIS

    May 1, 2007, 00:00

  • PHP33 PRELIMINARY EFFECTS OF A NEW NURSE-PHARMACIST CLINICAL PREVENTION PROGRAM ON MEDICATION USE

    May 1, 2007, 00:00

  • CV2 MEDICATION REFILL PERSISTENCE- DOES PRESCRIPTION COST-SHARING MATTER?

    May 1, 2007, 00:00

  • PEY6 THE RELATIVE COST-EFFECTIVENESS OF MULTIFOCAL INTRAOCULAR LENSES

    May 1, 2007, 00:00

  • PCN33 ANALYSIS OF DRUG REQUIREMENT FOR TREATMENT ADVANCED HODGKIN'S DISEASE

    May 1, 2007, 00:00

  • PCV25 THE ECONOMIC AND HEALTH CONSEQUENCES IN MEXICO OF MANAGING HYPERTENSION AND HYPERCHOLESTEROLEMIA WITH A SINGLE PILL THERAPY

    May 1, 2007, 00:00

  • PND29 THE IMPACT OF RESTLESS LEGS SYNDROME ON VARIOUS DIMENSIONS OF LIFE- RESULTS OF A WEB-BASED PATIENT SURVEY

    May 1, 2007, 00:00

  • PGI3 CONSTIPATION IN PERSONS RECEIVING HOSPICE CARE- PRELIMINARY ESTIMATES

    May 1, 2007, 00:00

  • PDB22 INFLUENCE OF HEMOGLOBIN A1C TEST RESULT ON DECISION TO INITIATE INSULIN SUPPLEMENTATION IN TYPE 2 DIABETES

    May 1, 2007, 00:00

  • PCV37 THE IMPACT OF CARE GAP IN MANAGING HIGH CARDIOVASCULAR RISK PATIENTS-A CANADIAN POPULATION ANALYSIS

    May 1, 2007, 00:00

  • PCN36 NEW SYSTEM OF COSTLY DRUG REIMBURSEMENT IN FRANCE-ASSESSMENT IN A TEACHING HOSPITAL ONCOLOGY DEPARTMENT

    May 1, 2007, 00:00

  • PSM3 ESTIMATING THE INCIDENCE AND PREVALENCE OF SMOKING RELATED MORBIDITIES USING PROXY VALUES

    May 1, 2007, 00:00

  • PCV47 BURDEN OF ILLNESS AMONG PATIENTS AT HIGH RISK FOR MAJOR CARDIOVASCULAR EVENTS

    May 1, 2007, 00:00

  • PEY2 PREVALENCE OF GLAUCOMATOUS RISK FACTORS IN PATIENTS FROM A MANAGED-CARE SETTING- A PILOT EVALUATION

    May 1, 2007, 00:00

  • WH4 ECONOMIC EVALUATION OF FEMALE VACCINATION WITH A QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINE IN NEW ZEALAND

    May 1, 2007, 00:00

  • PHM7 COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA DOSES ROUTINELY USED IN CLINICAL PRACTICE IN DEPARTMENT OF DEFENSE BENEFICIARIES

    May 1, 2007, 00:00

  • PCV32 IMPACT OF DEPRESSION ON HEALTH STATUS AND HEALTH CARE UTILIZATION IN PATIENTS WITH HYPERTENSION- RESULTS FROM THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS 2002-2003)

    May 1, 2007, 00:00

  • PCV49 DEVELOPMENT OF AN INTERACTIVE MODEL TO PREDICT LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL) REDUCTION AND LDL GOAL ATTAINMENT ASSOCIATED WITH STATIN USE IN ROUTINE CLINICAL PRACTICE

    May 1, 2007, 00:00

  • PHP22 HEALTH REIMBURSEMENT ACCOUNT BASED CONSUMER DRIVEN HEALTH PLANS-THEIR IMPACT ON MEDICAL UTILIZATION, PHARMACY UTILIZATION AND EXPENDITURES

    May 1, 2007, 00:00

  • PAA18 DATA EXTRACTION METHODS, ECONOMETRIC MODELING AND FACTORIAL ANALYSIS REVEAL CLINICALLY IMPORTANT PATIENT PROFILES IN CHRONIC ASTHMA

    May 1, 2007, 00:00

  • A Cost-Effectiveness Decision Model for Antiepileptic Drug Treatment in Newly Diagnosed Epilepsy Patients

    May 1, 2007, 00:00

  • CASE 1 REVIEWING THE REIMBURSEMENT STATUS OF PHARMACEUTICALS—EXPERIENCES FROM SWEDEN

    May 1, 2007, 00:00

  • PND6 COST-EFFECTIVENESS OF SCREENING FOR COGNITIVE IMPAIRMENT IN OLDER POPULATIONS- IMPLICATIONS FOR ALZHEIMER'S DISEASE CARE

    May 1, 2007, 00:00

  • PCV54 PROJECTED COST SAVINGS COMPARISON TO MANAGED CARE ORGANIZATIONS FOR THE YEAR FOLLOWING GENERIC SIMVASTATIN AND PRAVASTATIN AVAILABILITY IN THE US

    May 1, 2007, 00:00

  • PHP24 COMPARING MEDICATION ADHERENCE AND WASTAGE AMONG THREE DIFFERENT RETAIL PROGRAMS

    May 1, 2007, 00:00

  • PHP18 BENEFICIARY OUT-OF-POCKET-A CROSS-SECTIONAL PILOT STUDY IN THE SAUDI MINISTRY OF HEALTH HOSPITAL OUTPATIENT CLINICS

    May 1, 2007, 00:00

  • PIN32 ANALYSES FROM ROUTINE PATIENT CARE SETTINGS FOR CLINICAL RESEARCH PURPOSES

    May 1, 2007, 00:00

  • PGI16 VALIDATION OF GASTROINTESTINAL QUALITY OF LIFE INDEX FOR ASSESSMENT OF GALLSTONE-RELATED SYMPTOMS

    May 1, 2007, 00:00

  • PCN20 COST-OF-ILLNESS- ECONOMIC EVALUATION OF PALLIATIVE 153SM-LEXIDRONAM RADIONUCLIDE TREATMENT IN PATIENTS WITH BONE PAIN SECONDARY TO METASTATIC PROSTATE CANCER

    May 1, 2007, 00:00

  • PCV29 PHARMACOECONOMIC ANALYSIS OF EXTENDED PROPHYLAXIS BY ENOXAPARIN AFTER HIP JOINT REPLACEMENT

    May 1, 2007, 00:00

  • PHM6 LIFETIME ECONOMIC VALUE OF ORTHOPEDIC SURGERY WITH RECOMBINANT ACTIVATED FACTOR VII IN HEMOPHILIA PATIENTS WITH INHIBITORS

    May 1, 2007, 00:00

  • PHP29 REGULATION OF DRUG EXPENDITURES IN EUROPEAN COUNTRIES

    May 1, 2007, 00:00

  • PHM5 RESTROSPECTIVE STUDY OF OUTCOMES AND COSTS IN SICKLE CELL DISEASE (SCD) PATIENTS IN US

    May 1, 2007, 00:00

  • PAA24 ASTHMA CONTROL AND HEALTH-RELATED QUALITY OF LIFE IN CHILDREN

    May 1, 2007, 00:00

  • PHP13 THE TRENDS IN PRESCRIBING OF HERBAL MEDICINES IN AMBULATORY SETTINGS IN THE UNITED STATES 1993-2004

    May 1, 2007, 00:00

  • PHP25 TRENDS IN OUT OF POCKET COST BURDEN FOR PATIENTS WITH CHRONIC CONDITIONS

    May 1, 2007, 00:00

  • PMH1 CHANGES IN COMORBIDITIES, MEDICATION USE AND TREATMENT COSTS AFTER DIAGNOSIS OF GENERALIZED ANXIETY DISORDER

    May 1, 2007, 00:00

  • PDB12 RESOURCE UTILIZATION AND ECONOMIC COST OF CARE BASED ON A RANDOMIZED TRIAL OF V.A.C.® THERAPY IN THE TREATMENT OF DIABETIC FOOT ULCER WOUNDS

    May 1, 2007, 00:00

  • PCV33 ANALYSIS OF CLOPIDOGREL USE IN OUTPATIENT SETTINGS

    May 1, 2007, 00:00

  • PMC35 THE ISSUES THAT ARISE DURING THE TRANSLATION OF IVRS (INTERACTIVE VOICE RESPONSE SYSTEM) EPRO SCRIPTS

    May 1, 2007, 00:00

  • PDB9 DIRECT AND INDIRECT COSTS AND RESOURCE UTILIZATION ASSOCIATED WITH PHOTOCOAGULATION AND VITRECTOMY PROCEDURES AMONG EMPLOYEES WITH DIABETIC RETINOPATHY

    May 1, 2007, 00:00

  • PHP47 DETERMINING ANTIBIOTIC USE IN INDIA

    May 1, 2007, 00:00

  • MD2 PER-PATIENT-PER-MONTH DRUG COSTS IN MEDICARE PART D PROTECTED CLASSES

    May 1, 2007, 00:00

  • PCV57 HOW INFLUENTIAL ARE CLINICAL GUIDELINES FOR THE EVALUATION OF ACUTE CARDIAC SYMPTOMS? METHODOLOGY FOR THE INVESTIGATION OF NATIONAL CORONARY DISEASE IDENTIFICATION (INCIDENT)

    May 1, 2007, 00:00

  • PCV38 TREATMENT OF DEPRESSION IN CORONARY ARTERY DISEASE-A STUDY OF NATIONAL AMBULATORY MEDICAL CARE VISITS FROM 2000 TO 2004

    May 1, 2007, 00:00

  • PDB3 A RETROSPECTIVE EVALUATION OF HBA1C GOAL ATTAINMENT AMONG VARIOUS DIABETES TREATMENT REGIMENS IN A MANAGED CARE POPULATION

    May 1, 2007, 00:00

  • PND4 RESOURCE UTILIZATION PATTERNS WITH TOPIRAMATE FOR MIGRAINE PREVENTION IN THE MANAGED CARE SETTING

    May 1, 2007, 00:00

  • CS2 OUTCOMES ASSOCIATED WITH THE USE OF THIAZOLIDINEDIONES AMONG MEDICARE BENEFICIARIES WITH TYPE II DIABETES—AN INSTRUMENTAL VARIABLE APPROACH

    May 1, 2007, 00:00

  • PMH4 ADVERSE EVENT PROFILE ASSOCIATED WITH OFF-LABEL USE OF ANTIPSYCHOTIC MEDICATIONS

    May 1, 2007, 00:00

  • PCN56 RELATIONSHIP BETWEEN FUNCTIONAL STATUS AND SELF RATED HEALTH IN PATIENTS WITH PROSTATE CANCER- DATA FROM CAPSURE

    May 1, 2007, 00:00

  • PGI1 COMORBIDITIES DURING THE YEAR FOLLOWING DIAGNOSIS FOR PERSONS WITH AND WITHOUT GERD USING THE AGENCY FOR HEALTH RESEARCH AND QUALITY (AHRQ) 261 SPECIFIC CATEGORIES

    May 1, 2007, 00:00

  • PIN5 CLINICAL AND ECONOMIC OUTCOMES OF VANCOMYCIN FOR GRAM-POSITIVE INFECTIONS IN AN ERA OF INCREASING RESISTANCE-A SYSTEMATIC REVIEW

    May 1, 2007, 00:00

  • PIN37 LESSONS LEARNED IN EVALUATING THE IMPACT OF VACCINES ON HEALTH CARE UTILIZATION IN TWO LARGE RANDOMIZED CLINICAL TRIALS

    May 1, 2007, 00:00

  • PCASE7 INCLUDING A PHARMACOECONOMIC MODEL IN THE FORMULARY REVIEW PROCESS OF NEW

    May 1, 2007, 00:00

  • PEY3 THE ECONOMIC BURDEN OF GLAUCOMA-RELATED VISUAL IMPAIRMENT

    May 1, 2007, 00:00

  • PCN7 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT THERAPY WITH TRASTUZUMAB FOR HER2-POSITIVE EARLY BREAST CANCER IN POLISH SETTING

    May 1, 2007, 00:00

  • PAA2 EXACERBATION RATES FOR SINGLE VS. DUAL CONTROLLER THERAPY FOR MILD-PERSISTENT ASTHMA

    May 1, 2007, 00:00

  • PST7 DOES ADMINISTRATION MODE AFFECT ITEM HIERARCHY IN STROKE SPECIFIC QUALITY OF LIFE MEASURE, STROKE IMPACT SCALE?—TELEPHONE AND MAIL ADMINISTRATION METHODS

    May 1, 2007, 00:00

  • PAR7 EVALUATION OF PHARMACOLOGIC TREATMENTS OVER 30 MONTHS FOR OSTEOARTHRITIS USING A NATIONAL MANAGED CARE DATABASE

    May 1, 2007, 00:00

  • PIN29 DRUG PRICE, UTILIZATION AND SPENDING FOR ANTIRETROVIRAL MEDICATIONS IN U.S. MEDICAID PROGRAMS FROM 1991 TO 2005

    May 1, 2007, 00:00

  • PCN17 MEDICAL COST CONSIDERATIONS OF FIXED DOSING REGIMENS OF ERYTHROPOIETIC AGENTS IN PATIENTS WITH CHEMOTHERAPY-INDUCED ANEMIA

    May 1, 2007, 00:00

  • PMH2 DIVALPROEX SODIUM VERSUS VALPROIC ACID- DRUG UTILIZATION PATTERNS, PERSISTENCE RATES, AND PREDICTORS OF HOSPITALIZATION AMONG VA PATIENTS DIAGNOSED WITH BIPOLAR DISORDER

    May 1, 2007, 00:00

  • PR3 PREFERENCE VALUES FOR HEALTH STATES ASSOCIATED WITH COLON CANCER AND ITS TREATMENT

    May 1, 2007, 00:00

  • PIN19 COST-EFFECTIVENESS OF GARGLING FOR PREVENTION OF UPPER RESPIRATORY TRACT INFECTIONS

    May 1, 2007, 00:00

  • PCN15 COST-EFFECTIVENESS OF NEW TARGETED THERAPY SUNITINIB MALATE AS SECOND LINE TREATMENT IN METASTATIC RENAL CELL CARCINOMA IN ARGENTINA

    May 1, 2007, 00:00

  • MD4 MEDICAID PREFERRED DRUG LISTS' COSTS TO PHYSICIANS

    May 1, 2007, 00:00

  • PCV34 COST OF CONSUMABLES ASSOCIATED WITH CARDIOVASCULAR COMPUTED TOMOGRAPHY ANGIOGRAPHY- THE CARDIOLOGIST'S PERSPECTIVE

    May 1, 2007, 00:00

  • PCV2 CLINICAL EXPERIENCE IN DYSLIPIDEMIC PATIENTS TREATED EITHER WITH ROSUVASTATIN 10 MG/DAY OR EZETIMIBE/SIMVASTATIN 10/20 MG/DAY IN MEXICO CITY. A RETROSPECTIVE ANALYSIS

    May 1, 2007, 00:00

  • Estimating the Rate of Accumulating Drug Resistance Mutations in the HIV Genome

    May 1, 2007, 00:00

  • PMH8 FORECASTING U.S. MEDICAID PROGRAM EXPENDITURE ON ANTIDEPRESSANT DRUGS

    May 1, 2007, 00:00

  • PCN53 A COMPARISION OF THE PSYCHOMETRICS PROPERTIES OF HEALTH RELATED QUALITY OF LIFE INSTRUMENTS USED IN GLIOBLASTOMA MULTIFORME PATIENTS

    May 1, 2007, 00:00

  • PGI14 ONE WEEK VERSUS DAILY RECALL OF SYMPTOMS OF INFANT GERD- DOES IT MAKE A DIFFERENCE?

    May 1, 2007, 00:00

  • PPN4 ECONOMICS OF MORPHINE EQUIVALENT DAILY DOSES (MEDD)

    May 1, 2007, 00:00

  • PCN51 METHODS AND APPLICATION OF DATA COLLECTION TECHNOLOGY IN THE ELECTRONIC VELCADE® OBSERVATIONAL STUDY (EVOBS)

    May 1, 2007, 00:00

  • PAR16 A COMPARISON OF SWITCHING PATTERNS AMONG ANTITUMOR NECROSIS FACTORS (ANTI-TNFS) IN THE TREATMENT OF RHEUMATOID ARTHRITIS

    May 1, 2007, 00:00

  • PCV72 CHARACTERIZATION OF HYPERTENSIVE PATIENTS WHO MIGHT BENEFIT FROM A COMBINATION OF TWO DRUGS IN ONE PILL FOR REDUCTION OF CARDIOVASCULAR RISK

    May 1, 2007, 00:00

  • PDB25 HEALTH STATUS AND QUALITY OF LIFE IN TYPE 2 DIABETES MELLITUS- RELATIONSHIPS IN A CROSS-SECTIONAL STUDY

    May 1, 2007, 00:00

  • CASE 5 OUTCOMES RESEARCH FOR MILITARY VACCINATION POLICY-THE US ARMY ACCESSION SCREENING AND IMMUNIZATION PROGRAM

    May 1, 2007, 00:00

  • PCN2 ASSESSING THE NET HEALTH OUTCOMES OF A 4D ELECTROMAGNETIC TUMOR TRACKING SYSTEM DURING RADIOTHERAPY FOR CLINICALLY LOCALIZED PROSTATE CANCER-A HEALTH TECHNOLOGY ASSESSMENT OF THE CALYPSO® 4D LOCALIZATION SYSTEM WITH BEACON® TRANSPONDER ...

    May 1, 2007, 00:00

  • PPN11 COSTS OF ERRORS ATTRIBUTABLE TO INTRAVENOUS PATIENT CONTROLLED ANALGESIA—FOCUS ON MEDICATION-RELATED ERRORS

    May 1, 2007, 00:00

  • PIH10 BURDEN OF PREMENSTRUAL DYSPHORIC DISORDER ON HEALTH-RELATED QUALITY OF LIFE

    May 1, 2007, 00:00

  • PND3 THE BUDGETARY IMPACT OF THE UTILIZATION OF NATALIZUMAB FOR THE TREATMENT OF RELAPSING MULTIPLE SCLEROSIS

    May 1, 2007, 00:00

  • PCV44 EFFECTS OF MEDICAID ACCESS RESTRICTIONS ON STATIN UTILISATION FOR PATIENTS TREATED BY PHYSICIANS PRACTISING IN POOR AND MINORITY NEIGHBORHOODS

    May 1, 2007, 00:00

  • PUK12 THE COST-EFFECTIVENESS OF MYCOPHENOLATE MOFETIL (MMF) AS FIRST-LINE THERAPY IN ACTIVE LUPUS NEPHRITIS

    May 1, 2007, 00:00

  • PDB11 THE COST-EFFECTIVENESS OF VACUUM ASSISTED CLOSURE® (V.A.C.) THERAPY FOR THE TREATMENT OF DIABETIC FOOT WOUNDS

    May 1, 2007, 00:00

  • OB1 IMPACT OF OBESITY SEVERITY ON HEALTH CONDITIONS AND MEDICAL COSTS IN THE US

    May 1, 2007, 00:00

  • PCV31 COST-EFFECTIVENESS OF ACHIEVING ADDITIONAL LIPID TARGETS WHEN SUBSTITUTING FENOFIBRATE 145 MG FOR STANDARD FENOFIBRATE THERAPY

    May 1, 2007, 00:00

  • PHP31 EXAMINATION OF THE VALUE OF LAB DATA IN HEALTH CARE MANAGEMENT

    May 1, 2007, 00:00

  • PEY13 ADJUNCTIVE THERAPY USE BY GLAUCOMA PATIENTS ON ORAL ANTIHYPERTENSIVES

    May 1, 2007, 00:00

  • PCV55 BLOOD PRESSURE CONTROL THROUGH PATIENT AND PHYSICIAN EDUCATION PROGRAMS

    May 1, 2007, 00:00

  • PIN3 TREATMENT FAILURE, COMPLICATIONS AND COSTS OF LEVOFLOXACIN VS.AMOXICILLIN/CLAVULANATE ANTIBIOTIC THERAPY IN OUTPATIENT COMMUNITY ACQUIRED PNEUMONIA (CAP)

    May 1, 2007, 00:00

  • PND10 AN ANALYSIS OF THE HEALTH AND PRODUCTIVITY BURDEN OF INSOMNIA AND ITS TREATMENT

    May 1, 2007, 00:00

  • MC4 TIME HORIZON BIAS IN ECONOMIC EVALUATIONS

    May 1, 2007, 00:00

  • PSM2 THE COST UTILITY OF VARENICLINE IN SMOKING CESSATION HEALTH PROGRAMMES IN SWEDEN

    May 1, 2007, 00:00

  • PSU3 SAVINGS OF THE USE OF RHBMP-2 IN OPEN TIBIA FRACTURES FOR EUROPEAN HEALTH CARE SYSTEMS FROM A PAYER AND SOCIETAL PERSPECTIVE

    May 1, 2007, 00:00

  • PO11 THE CONNECTION BETWEEN 5 YEARS MORTALITY FOLLOWING FEMORAL NECK FRACTURE AND ITS RISK FACTORS

    May 1, 2007, 00:00

  • RS2 INCREMENTAL COSTS ASSOCIATED WITH ANTIBIOTICS PRESCRIBED FOR COMMUNITY ACQUIRED PNEUMONIA

    May 1, 2007, 00:00

  • PHP34 EXAMINING THE ASSOCIATION BETWEEN EXPOSURE RATES TO CLINICALLY IMPORTANT DRUG-DRUG INTERACTIONS AND PHARMACEUTICAL SERVICES WITHIN AMBULATORY CARE SETTING IN VETERANS AFFAIRS MEDICAL CENTERS

    May 1, 2007, 00:00

  • PUK2 OUTCOMES AND COSTS ASSOCIATED WITH IMMUNOSUPPRESSION COMPLIANCE

    May 1, 2007, 00:00

  • PPN16 PRESCRIBING OF FENTANYL PATCHES TO NON-OPIOID TOLERANT PATIENTS IN THE MILITARY HEALTH SYSTEM (MHS)

    May 1, 2007, 00:00

  • PMC1 FORECASTING WITH TIME SERIES MODELS TO EXAMINE THE AVAILABILITY OF INPATIENT BEDS

    May 1, 2007, 00:00

  • PCN40 PATTERNS OF TREATMENT OF NON SMALL CELL LUNG CANCER (NSCLC) IN COMMUNITY PRACTICE

    May 1, 2007, 00:00

  • PCN1 COLONIC STENTING VERSUS SURGERY FOR MALIGNANT LARGE BOWEL OBSTRUCTION- COMPARATIVE ASSESSMENT OF OUTCOMES AND COST

    May 1, 2007, 00:00

  • CN4 PSYCHOMETRIC VALIDATION OF A PATIENT SYMPTOM ASSESSMENT-LUNG CANCER (PSALC) INSTRUMENT FOR SMALL CELL LUNG CANCER (SCLC)

    May 1, 2007, 00:00

  • PCV53 PROFILES OF INITIAL DRUG THERAPIES AMONG NEWLY DIAGNOSED HYPERTENSIVE PATIENTS WITH NO COMPELLING INDICATIONS

    May 1, 2007, 00:00

  • PND26 MEASUREMENT OF QUALITY OF LIFE IN RESTLESS LEGS SYNDROME

    May 1, 2007, 00:00

  • PCN13 COST-EFFECTIVENESS ANALYSIS OF DOCETAXEL VERSUS OTHER REGIMENS IN THE ADJUVANT THERAPY OF EARLY AND LOCALLY ADVANCED BREAST CANCER IN POLAND

    May 1, 2007, 00:00

  • PRS12 PROPENSITY OF PRESCRIBING FLUTICASONE/SALMETEROL COMBINATION IN A HIGH RISK MEDICAID POPULATION

    May 1, 2007, 00:00

  • PCASE13 OTC PROGRAM FOR COMMON, ROUTINE AILMENTS DESIGNED TO LOWER THE BURDEN ON PROVIDERS AND TO SUBSTITUTE LESS EXPENSIVE OTC MEDICATIONS FOR MORE COSTLY PRESCRIPTION MEDICATIONS-A CASE STUDY OF THE UNITED STATES NAVAL HOSPITAL IN KEFLAVI ...

    May 1, 2007, 00:00

  • CS4 A METHODOLOGY FOR PROJECTING DISEASE PREVALENCE, TREATMENT, AND EXPENDITURES FOR THE US EMPLOYERINSURED POPULATION

    May 1, 2007, 00:00

  • PCV13 METABOLIC SYNDROME PREVALENCE IN A HYPERTENSIVE POPULATION

    May 1, 2007, 00:00

  • PCN3 CORRELATION BETWEEN TIME TO PROGRESSION AND OVERALL SURVIVAL IN PATIENTS WITH METASTATIC BREAST CANCER

    May 1, 2007, 00:00

  • PCN38 WITHIN COUNTRY DIFFERENCES IN MAMMOGRAPHY COVERAGE OF THE HUNGARIAN NATIONWIDE ORGANIZED BREAST CANCER SCREENING PROGRAMME

    May 1, 2007, 00:00

  • PMH7 SUICIDALITY AND ANTIDEPRESSANTS USE IN CHILDREN AND ADOLESCENTS

    May 1, 2007, 00:00

  • PMC24 PSYCHOMETRIC EVALUATION OF INSTRUMENTS USED TO MEASURE PATIENT SATISFACTION WITH PHARMACIST SERVICES

    May 1, 2007, 00:00

  • Substantial Treatment Overuse in the United States?—Response to Grandjour

    May 1, 2007, 00:00

  • PGI18 GASTROESOPHAGEAL REFLUX DISEASE AND HEALTHRELATED QUALITY OF LIFE IN THE GENERAL POPULATION OF SHANGHAI, CHINA

    May 1, 2007, 00:00

  • PST6 GENERIC AND DISEASE-SPECIFIC HEALTH RELATED QUALITY OF LIFE (HRQOL) IN STROKE SURVIVORS

    May 1, 2007, 00:00

  • The Relationship between Influenza Vaccination and Outpatient Visits for Upper Respiratory Infection by the Elderly in Taiwan

    Mar 1, 2007, 00:00

  • The Cost-Effectiveness of Expanding Newborn Screening for up to 21 Inherited Metabolic Disorders Using Tandem Mass Spectrometry- Results from a Decision-Analytic Model

    Mar 1, 2007, 00:00

  • Economic Burden of Osteoporosis-Related Fractures in Medicaid

    Mar 1, 2007, 00:00

  • The Author's Reply to Comment on “Where's the Value in Health Care?”

    Mar 1, 2007, 00:00

  • The Impact of Atrial Fibrillation on the Cost of Stroke- The Berlin Acute Stroke Study

    Mar 1, 2007, 00:00

  • The Cost-Effectiveness of Influenza Vaccination for People Aged 50 to 64 Years- An International Model

    Mar 1, 2007, 00:00

  • Effect of Second-Generation Antidepressants on Mania- and Depression-Related Visits in Adults with Bipolar Disorder- A Retrospective Study

    Mar 1, 2007, 00:00

  • Reduced Mortality Rates after Intensive Statin Therapy in Managed-Care Patients

    Mar 1, 2007, 00:00

  • Comment on “Where's the Value in Health Care?”

    Mar 1, 2007, 00:00

  • Health-Related Quality of Life Measured with EQ-5D in Patients Treated for Depression in Primary Care

    Mar 1, 2007, 00:00

  • Cost-Effectiveness Analysis of a Quality-Controlled Mammography Screening Program from the Swiss Statutory Health-Care Perspective- Quantitative Assessment of the Most Influential Factors

    Jan 1, 2007, 00:00

  • Economic Evaluation of Palliative Management versus Peritoneal Dialysis and Hemodialysis for End-Stage Renal Disease- Evidence for Coverage Decisions in Thailand

    Jan 1, 2007, 00:00

  • Cardioverter Defibrillators in Primary Prevention of Sudden Cardiac Death- A Cost or an Investment?

    Jan 1, 2007, 00:00

  • A Checklist for Medication Compliance and Persistence Studies Using Retrospective Databases

    Jan 1, 2007, 00:00

  • Is It Time for Managed Care Organizations to Cover Weight Reduction?

    Jan 1, 2007, 00:00

  • The Effect of Disease, Functional Status, and Relapses on the Utility of People with Multiple Sclerosis in the UK

    Jan 1, 2007, 00:00

  • The Cost-Effectiveness of Lanthanum Carbonate in the Treatment of Hyperphosphatemia in Patients with End-Stage Renal Disease

    Jan 1, 2007, 00:00

  • Assessment of Cardiometabolic Risk Factors in a National Primary Care Electronic Health Record Database

    Jan 1, 2007, 00:00

  • Economic Burden and Risk of Cardiovascular Disease and Diabetes in Patients with Different Cardiometabolic Risk Profiles

    Jan 1, 2007, 00:00

  • Metabolic Syndrome and Employer Sponsored Medical Benefits- An Actuarial Analysis

    Jan 1, 2007, 00:00

  • Cost-Effectiveness of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy

    Jan 1, 2007, 00:00

  • Predicting the Prevalence of Cardiometabolic Risk Factors When Clinical Data Are Limited

    Jan 1, 2007, 00:00

  • Using EQ-5D to Derive General Population-based Utilities for the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA)

    Jan 1, 2007, 00:00

  • Special Issue- Exploring Cardiometabolic Complications of Obesity and Related Risk Factors- Prevalence and Economic Consequences

    Jan 1, 2007, 00:00

  • Foreword- Exploring Cardiometabolic Complications of Obesity and Related Risk Factors- Prevalence and Economic Consequences

    Jan 1, 2007, 00:00

  • Age-Specific Impact of Obesity on Prevalence and Costs of Diabetes and Dyslipidemia

    Jan 1, 2007, 00:00

  • Cost-Benefit Analysis of Preventing Sudden Cardiac Deaths with an Implantable Cardioverter Defibrillator versus Amiodarone

    Jan 1, 2007, 00:00

  • Simple Demographic Model to Predict Multiple Cardiometabolic Risk Factors in Two Well-Known Observational Cohorts

    Jan 1, 2007, 00:00

  • Cardiovascular Risk Factor Clusters and Employment in the United States

    Jan 1, 2007, 00:00

  • PRS3 COST-EFFECTIVENESS OF ROFLUMILAST IN THE UK-A 1-YEAR STUDY IN PATIENTS WITH SEVERE TO VERY SEVERE COPD

    Nov 1, 2006, 00:00

  • PSU3 DEMOGRAPHIC PREDICTORS OF RESOURCE UTILIZATION AND COSTS OF SOLID ORGAN TRANSPLANTATION IN BRITISH COLUMBIA, CANADA

    Nov 1, 2006, 00:00

  • PMH19 IMPACT OF REMISSION IN MAJOR DEPRESSIVE DISORDER ON ECONOMIC BURDEN OF ILLNESS IN SWEDEN

    Nov 1, 2006, 00:00

  • PUK20 PATIENTS UNDER 65 YEARS OF AGE ON RENAL TRANSPLANT WAITING LISTS SHOW A WORSE PERCEIVED STATE OF HEALTH THAN OLDER ONES

    Nov 1, 2006, 00:00

  • PMH41 ANXIETY DISORDERS- THE PATIENTS' PERSPECTIVE

    Nov 1, 2006, 00:00

  • PMC9 A REVIEW OF FACTORS AFFECTING THERAPEUTIC COMPLIANCE

    Nov 1, 2006, 00:00

  • OA2 SCREENING FOR PATIENTS AT RISK FOR OSTEOPOROSIS BASED ON A RISK-QUESTIONNAIRE IN A GERMAN SETTING OF COMMUNITY PHARMACIES

    Nov 1, 2006, 00:00

  • PHP2 RACIAL/ETHNIC DISPARITIES IN PRESCRIPTION DRUG UTILIZATION AND OUT-OF-POCKET COSTS

    Nov 1, 2006, 00:00

  • PCN38 “COST OF ILLNESS” ANALYSIS OF RENAL CELL CARCINOMA

    Nov 1, 2006, 00:00

  • PMH40 ASSESSING SELECTION BIAS ON TREATMENT EFFECTS IN OBSERVATIONAL STUDIES WITH REPEATED OUTCOME MEASURES- REGRESSION, PROPENSITY SCORING, FIXEDEFFECTS MODELS, AND BAYESIAN ESTIMATION METHODS

    Nov 1, 2006, 00:00

  • POS16 LONG TERM QUALITY OF LIFE RELATED TO OSTEOPOROTIC FRACTURES; 13–18 MONTHS AFTER FRACTURE

    Nov 1, 2006, 00:00

  • MC2 15DS-A NEW DYNAMIC QUALITY OF LIFE TOOL WITH INCREASED SENSITIVITY AND IMPROVED COMPOSITE STRUCTURE FOR RECALL BIAS AND RESPONSE SIFT ADJUSTMENTS

    Nov 1, 2006, 00:00

  • ES1 COST-UTILITY ANALYSES OF NEW MEDICAL TECHNOLOGIES- OFTEN COST-EFFECTIVE, SOMETIMES COST-INEFFECTIVE, DOMINANT, OR DOMINATED, BUT ALMOST NEVER ‘DECREMENTALLY’ COST-EFFECTIVE

    Nov 1, 2006, 00:00

  • PMH16 COST EFFECTIVENESS MODEL COMPARING FAST DISSOLVING OLANZAPINE AND CONVENTIONAL OLANZAPINE TABLETS IN THE TREATMENT OF SCHIZOPHRENIA

    Nov 1, 2006, 00:00

  • PCN35 BURDEN OF ILLNESS OF RENAL CELL CARCINOMA IN SPAIN

    Nov 1, 2006, 00:00

  • POS9 COMPARISON OF THE BURDEN OF ILLNESS OF DISPLACED AND UNDISPLACED FEMORAL NECK FRACTURE AFTER REDUCTION INTERNAL FIXATION

    Nov 1, 2006, 00:00

  • PCN15 CAPECITABINE VS. BOLUS 5-FU/LV AS ADJUVANT THERAPY FOR PATIENTS WITH DUKES' C COLON CANCER- PHARMACOECONOMIC EVALUATION OF X-ACT TRIAL– DATA FROM CZECH PERSPECTIVE

    Nov 1, 2006, 00:00

  • PHM7 DIRECT COST OF BETA THALASSEMIA MAJOR- RESUTS FROM THE ITHACA STUDY

    Nov 1, 2006, 00:00

  • PUK6 COST-EFFECTIVENESS OF TREATMENT WITH EPOIETIN ALPHA FOR PATIENTS WITH ANAEMIA DUE TO RENAL FAILURE—THE CASE OF SWEDEN

    Nov 1, 2006, 00:00

  • PUK22 COMPARISON OF THE PRO ENDPOINTS FOUND IN LABELING CLAIMES OF URINARY INCONTINENCE DRUGS WITH THOSE RECOMMENDED BY THE CORRESPONDING EMEA NOTE FOR GUIDANCE

    Nov 1, 2006, 00:00

  • IN3 RELATIONSHIP BETWEEN ADHERENCE TO ANTIRETROVIRAL THERAPY AND THE COST-EFFECTIVENESS OF ANTIRETROVIRAL THERAPY

    Nov 1, 2006, 00:00

  • PHP33 OCCUPATIONAL INJURIES- USE AND COST OF EMERGENCY DEPARTMENT FOR TREATMENT OF ACCIDENTAL HYPODERMIC NEEDLE PUNCTURES

    Nov 1, 2006, 00:00

  • PMC14 MEASURING PATIENT-REPORTED SIDE EFFECTS OF DRUGS- ITS IMPORTANCE AND METHODOLOGICAL CHALLENGES

    Nov 1, 2006, 00:00

  • PMH35 REDUCTION IN SUICIDAL IDEATION AND VIOLENT BEHAVIOUR AFTER SIX MONTHS OF TREATMENT WITH LONG ACTING RISPERIDONE IN PATIENTS ENROLLED IN THE ELECTRONIC SCHIZOPHRENIA ADHERENCE TREATMENT REGISTRY (E-STAR)

    Nov 1, 2006, 00:00

  • PCN30 ECONOMIC EVALUATION OF FOLFOX4 VERSUS FOLFOX7 WITH OXALIPLATIN STOP-AND-GO IN ADVANCED COLORECTAL CANCER PATIENTS

    Nov 1, 2006, 00:00

  • PMC13 EMPIRICAL RESEARCH FOR WILLINGNESSTO PAYFOR ONE QALY GAIN

    Nov 1, 2006, 00:00

  • PCV14 ASCOT-LIKE PATIENT PREVALENCE AMONG THE HYPERTENSIVES IN SPAIN

    Nov 1, 2006, 00:00

  • PIN24 THE USE OF ANTIBIOTICS IN CHILDREN POPULATION IN BELGRADE REGION

    Nov 1, 2006, 00:00

  • PCV32 COST-EFFECTIVENESS OF CLOPIDOGREL IN MYOCARDIAL INFARCTION WITH ST-SEGMENT ELEVATION- EUROPEAN MODEL RESULTS BASED ON CLARITY AND COMMIT

    Nov 1, 2006, 00:00

  • PCV3 DO WE FOLLOW THE GUIDELINES ON PREVENTION OF CARDIOVASCULAR DISEASE IN OUT-PATIENT CARE?

    Nov 1, 2006, 00:00

  • PEY23 VISION WITH RESTOR® VERSUS MONOFOCAL INTRAOCULAR LENSES (IOL) AFTER CATARACT SURGERY- RESULTS OF A POOLED ANALYSIS

    Nov 1, 2006, 00:00

  • PDB41 EFFECT OF COMPLICATIONS ON HEALTH RELATED QUALITY OF LIFE IN HUNGARIAN INSULIN TREATED DIABETIC PATINETS

    Nov 1, 2006, 00:00

  • PCV40 A COST-EFFECTIVENESS ANALYSIS OF CARDIAC REHABILITATION AFTER PERCUTANEOUS CORONARY INTERVENTIONS

    Nov 1, 2006, 00:00

  • PCV9 NON-PERSISTENT USE OF ANTIHYPERTENSIVE DRUGS LEADS TO INCREASED RISK OF HOSPITALIZATIONS FOR ACUTE MYOCARDIAL INFARCTION OR STROKE

    Nov 1, 2006, 00:00

  • PND4 PREGABALIN VS GABAPENTIN IN THE TREATMENT OF NEUROPATHIC PAIN IN ITALY- A COST-EFFECTIVENESS ANALYSIS

    Nov 1, 2006, 00:00

  • PEY27 DEVELOPMENT OF A QUESTIONNAIRE ASSESSING PATIENT SATISFACTION WITH EYE DROPS IN OCULAR HYPERTENSION AND GLAUCOMA

    Nov 1, 2006, 00:00

  • POS1 EFFECT OF COMORBIDITIES ON THE EARLY MORTALITY AFTER FEMORAL NECK FRACTURE IN ELDERLY IN HUNGARY

    Nov 1, 2006, 00:00

  • PEY16 COST-UTILITY ANALYSIS FOR PEGAPTANIB IN AGE-RELATED MACULAR DEGENERATION IN THE UK- THE IMPACT OF DEMOGRAPHIC AND DISEASE CHARACTERISTICS

    Nov 1, 2006, 00:00

  • PIN23 INDICATOR OF ANTIBIOTIC USE IN PUBLIC PHARMACY CHAIN BELGRADE

    Nov 1, 2006, 00:00

  • CV5 PHARMACOECONOMIC EVALUATION OF SIMVASTATIN VERSUS “NO TREATMENT” IN PRIMARY AND SECONDARY PREVENTION OF CORONARY HEART DISEASE (CHD) IN POLAND

    Nov 1, 2006, 00:00

  • PCV31 HEALTH ECONOMIC ASSESSMENT OF RAISING HDL-C WITH PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) WHEN ADDED TO STATIN THERAPY IN PATIENTS WITH DYSLIPIDEMIA AND TYPE 2 DIABETES-AN ANALYSIS FOR SWEDEN

    Nov 1, 2006, 00:00

  • POB3 BURDEN OF ILLNESS OF ABDOMINAL OBESITY- A RETROSPECTIVE CHART REVIEW

    Nov 1, 2006, 00:00

  • PCV11 CLINICAL EFFECTIVENESS OF BETALOC ZOC COMPARED TO METOPROLOL TARTRATE OR CARVEDILOL IN HYPERTENSION TREATMENT

    Nov 1, 2006, 00:00

  • PHM3 HEPARIN-RELATED THROMBOCYTOPENIA ASSOCIATED WITH MAJOR INCREASE IN HOSPITAL COSTS

    Nov 1, 2006, 00:00

  • PGI16 ARE ADULTS MORE AVERSE TO TREATMENT RISKS FOR THEIR CHILDREN THAN THEY ARE FOR THEMSELVES?

    Nov 1, 2006, 00:00

  • PCN31 A COST MINIMISATION ANALYSIS OF NAVELBINE-CISPLATIN VERSUS GEMCITABINE-CISPLATIN IN ADVANCED NONSMALL CELL LUNG CANCER IN POLAND

    Nov 1, 2006, 00:00

  • PCV73 ANALYSIS OF COST AND EFFECTIVENESS DATA USING RANDOM PERMUTATION METHODS

    Nov 1, 2006, 00:00

  • CN1 TREATMENTS FOR METASTATIC MELANOMA- SYNTHESIS OF EVIDENCE FROM RANDOMIZED TRIALS

    Nov 1, 2006, 00:00

  • PDB4 AN EVALUATION OF THE COST OF DIABETES-RELATED MEDICATION FOLLOWING INITIATION OF TREATMENT WITH INSULIN GLARGINE VERSUS INSULIN DETEMIR IN THE UK FROM OBSERVATIONAL, REAL-LIFE DATA FROM GENERAL PRACTICE

    Nov 1, 2006, 00:00

  • PGI6 THE USE OF BUDGET IMPACT MODELLING TO ASSESS THE ECONOMIC CONSEQUENCE OF CHANGING THE PRESCRIPTION PATTERN OF PROTON PUMP INHIBITORS (PPI) IN SWEDEN

    Nov 1, 2006, 00:00

  • PND12 A LITERATURE REVIEW OF PATIENT-REPORTED OUTOMES (PROS), NEUROPSYCHOLOGICAL AND COGNITIVE INSTRUMENTS IN PARKINSON'S DISEASE

    Nov 1, 2006, 00:00

  • PAR8 TRENDS IN PRESCRIPTION CLAIMS FOLLOWING THE WITHDRAWAL OF ROFECOXIB FROM THE CANADIAN MARKET

    Nov 1, 2006, 00:00

  • PGI1 IS COMBINATION THERAPY OF LAMIVUDINE WITH INTERFERON-ALPHA SUPERIOR TO LAMIVUDINE MONOTHERAPY FOR HBEAG-POSITIVE CHRONIC HEPATITIS B? A META-ANALYSIS OF RANDOMIZED TRIALS

    Nov 1, 2006, 00:00

  • PND5 TREATMENT OF EARLY PARKINSONIAN PATIENTS WITH RASAGILINE OR ROPINIROLE. WHAT IS THE MOST COSTEFFECTIVE TREATMENT STRATEGY IN FINLAND?

    Nov 1, 2006, 00:00

  • PIH6 ECONOMIC EVALUATION OF CARBETOCINE FOR THE PREVENTION OF UTERINE ATONY IN PATIENTS WITH RISK FACTORS IN MEXICO

    Nov 1, 2006, 00:00

  • PEY2 EFFECTIVENESS OF TRAVOPROST VERSUS DORZOLAMIDE + TIMOLOL FIXED COMBINATION IN FIRST LINE TREATMENT OF GLAUCOMA-ANALYZED FROM THE UK GENERAL PRACTITIONER RESEARCH DATABASE

    Nov 1, 2006, 00:00

  • PCV25 COST-EFFECTIVENESS OF CLOPIDOGREL IN MEXICO- WITHIN TRIAL ANALYSIS

    Nov 1, 2006, 00:00

  • PCN47 COUNTY LEVEL INEQUALITIES IN THE ATTENDANCE OF THE HUNGARIAN ORGANIZED NATIONWIDE CERVICAL CANCER SCREENING PROGRAMME

    Nov 1, 2006, 00:00

  • PDB8 THE IMPACT OF IMPROVED BETA-CELL FUNCTION ON MODELLING THE COST-EFFECTIVENESS OF ROSIGLITAZONE IN THE MANAGEMENT OF TYPE 2 DIABETES IN SPAIN

    Nov 1, 2006, 00:00

  • PIN1 CLINICAL AND ECONOMIC IMPACT OF INTRODUCING A QUADRIVALENT (6, 11, 16, 18) HUMAN PAPILLOMAVIRUS VACCINE IN SWITZERLAND

    Nov 1, 2006, 00:00

  • PMH32 ANALYSIS OF A MULTINATIONAL, CROSS-SECTIONAL SURVEY OF PHYSICIAN DESCRIPTIONS AND PERCEPTIONS OF PATIENTS WITH NEGATIVE SYMPTOMS OF SCHIZOPHRENIA

    Nov 1, 2006, 00:00

  • Impact of Rofecoxib Withdrawal on Cyclooxygenase-2 Utilization among Patients with and without Cardiovascular Risk

    Nov 1, 2006, 00:00

  • DISCLOSURE INFORMATION

    Nov 1, 2006, 00:00

  • PCN50 BOWEL CANCER SCREENING. BALANCING COSTEFFECTIVENESS AND AFFORDABILITY

    Nov 1, 2006, 00:00

  • PIN18 COST-UTILITY ANALYSIS OF TREATMENT ALTERNATIVES IN PATIENTS WITH HBEAG POSITIVE CHRONIC HEPATITIS B

    Nov 1, 2006, 00:00

  • PDB45 EXPERIENCE OF HYPOGLYCEMIA IS SIGNIFICANTLY ASSOCIATED WITH LOWER QUALITY OF LIFE (EUROQOL) IN DIABETIC PATIENTS TREATED WITH METFORMIN (MF) IN COMBINATION WITH A SULPHONYLUREA (SU) IN FRANCE

    Nov 1, 2006, 00:00

  • PAA8 A COMPARISON OF CLAIMS RATIO BETWEEN PRIMARY AND SECONDARY DRUGS IN THE MANAGEMENT OF ASTHMA. A CANADIAN ANALYSIS

    Nov 1, 2006, 00:00

  • PDB12 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION VERSUS MULTIPLE DAILY INJECTION OF INSULIN IN PATIENTS WITH TYPE 1 DIABETES-A LONG-TERM HEALTH ECONOMIC ANALYSIS IN THE NORWEGIAN AND SWEDISH SETTINGS

    Nov 1, 2006, 00:00

  • PMH6 MENTAL HEALTH IN THE FIRST MONTHS OF HEMODIALYSIS AS A PREDICTOR OF SURVIVAL

    Nov 1, 2006, 00:00

  • PCN37 COMPARING MANAGEMENT PATTERNS AND ASSOCIATED COSTS FOR WOMEN WITH ABNORMAL CERVICAL CYTOLOGY IN 5 DIFFERENT COUNTRIES

    Nov 1, 2006, 00:00

  • PSK2 MEDICATION ADHERENCE AND HEALTH CARE COSTS ASSOCIATED WITH BIOLOGICS IN MEDICAID-ENROLLED PATIENTS WITH PSORIASIS

    Nov 1, 2006, 00:00

  • PHP34 PHYSICIANS' ATTITUDES TO AND EXPERIENCE WITH INCREASED USE OF INDIVIDUAL REIMBURSEMENT VERSUS GENERAL REIMBURSEMENT OF NEW IMPORTANT PHARMACEUTICALS

    Nov 1, 2006, 00:00

  • PSK3 A COST-EFFECTIVENESS ANALYSIS OF BIOLOGIC THERAPIES FOR THE TREATMENT OF CHRONIC PLAQUE PSORIASIS

    Nov 1, 2006, 00:00

  • PIH2 HEALTH ECONOMIC CONSEQUENCES OF THE CHOICE OF FOLLICLE STIMULATING HORMONE ALTERNATIVES IN IVF TREATMENT

    Nov 1, 2006, 00:00

  • PCN62 UTILITY ELICITATION IN PATIENTS WITH FOLLICULAR LYMPHOMA

    Nov 1, 2006, 00:00

  • PSK9 QUALITY OF LIFE OF ADULT PATIENTS WITH ATOPIC DERMATITIS- THE CODA STUDY

    Nov 1, 2006, 00:00

  • PCV61 INITIAL PHARMACOTHERAPY FOR PATIENTS WITH DYSLIPIDEMIA IN PRIMARY CARE

    Nov 1, 2006, 00:00

  • PCN51 PHYSICIAN AND PATIENT CHARACTERISTICS ASSOCIATED WITH OUTPATIENT BREAST CANCER SCREENING RECOMMENDATIONS-ANALYSIS OF US OUTPATIENT DATA 1996–2004

    Nov 1, 2006, 00:00

  • PCN36 BURDEN OF CERVICAL CANCER IN POLAND

    Nov 1, 2006, 00:00

  • PRS19 EPIDEMIOLOGICAL STUDY TO INVESTIGATE PATIENTS' VIEWS ON CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

    Nov 1, 2006, 00:00

  • PDB39 THE IMPACT ON QUALITY OF LIFE BY CONVERTING THE TREATMENT OF TYPE 2 DIABETIC PATIENTS FROM CONVENTIONAL INSULIN REGIMENT TO ORAL TREATMENT WITH PIOGLITAZONE

    Nov 1, 2006, 00:00

  • PMC11 EFFECTIVE USE OF ELECTRONIC DATA CAPTURE (EDC) TO IMPROVE THE QUALITY AND EFFICIENCY OF THE ANALYSIS OF PATIENT REPORTED OUTCOMES

    Nov 1, 2006, 00:00

  • PMH21 COST-UTILITY ANALYSIS OF ANTIDEPRESSANTS FOR SECOND-LINE TREATMENT OF MAJOR DEPRESSIVE DISORDER

    Nov 1, 2006, 00:00

  • DB1 RATES AND RISKS OF STARTING INSULIN IN DIABETES MELLITUS TYPE-2 PATIENTS

    Nov 1, 2006, 00:00

  • PHP41 AN ASSESMENT OF TWO IRANIAN SOCIAL SECURITY ORGANIZATION HOSPITALS PERFORMANCE BASED ON THE EFQM MODEL

    Nov 1, 2006, 00:00

  • PAA3 COST OF MANAGING ASTHMA EXACERBATIONS WITH STABLE DOSING OF SALMETEROL/FLUTICASONE COMBINED PRODUCT (SFC) COMPARED WITH ADJUSTABLE MAINTENANCE DOSING (AMD) OF FORMOTEROL/BUDESONIDE COMBINED PRODUCT (FBC) IN POLAND

    Nov 1, 2006, 00:00

  • PDB38 ADHERENCE TO STATIN TREATMENT IN PEOPLE WITH TYPE 1 AND TYPE 2 DIABETES

    Nov 1, 2006, 00:00

  • PAR2 ZOLEDRONIC ACID IN THE LONG-TERM MANAGEMENT OF PAGET'S DISEASE OF THE BONE IN GERMANY-A COSTSAVING APPROACH?

    Nov 1, 2006, 00:00

  • PCN14 COST-EFFECTIVENESS STUDY OF AN ASPIRIN CHEMOPREVENTION ASSOCIATED OR NOT WITH A COLONOSCOPIC SURVEILLANCE IN THE COLORECTAL CANCER

    Nov 1, 2006, 00:00

  • PCV68 CLOPIDOGREL PATTERNS OF USE IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN 5 EUROPEAN COUNTRIES

    Nov 1, 2006, 00:00

  • SZ1 EFFECTIVENESS AND COSTS OF ATYPICAL VERSUS TYPICAL ANTIPSYCHOTIC TREATMENT FOR SCHIZOPHRENIA IN ROUTINE CARE

    Nov 1, 2006, 00:00

  • PCN23 ADDING RITUXIMAB TO STANDARD CHEMOTHERAPY IS COST NEUTRAL AND CLINICALLY SUPERIOR IN ADVANCED STAGE NON-HODGKIN'S LYMPHOMA (NHL)

    Nov 1, 2006, 00:00

  • PCV70 MANAGEMENT AND OUTCOMES IN THE CARE OF ATRIAL FIBRILLATION IN GERMANY (MOCA)

    Nov 1, 2006, 00:00

  • PSU2 ECONOMIC EVALUATION COMPARING FROM HOME TO OPERATION AND CONVENTIONAL PROCESS OF LAPAROSCOPIC CHOLECYSTECTOMY- PROSPECTIVE RANDOMIZED CONTROLLED TRIAL

    Nov 1, 2006, 00:00

  • PGI12 GASTROINTESTINAL COMPLICATIONS INDUCED BY NONSTERIODAL ANTI-INFLAMMATORY DRUGS (NSAID)- EPIDEMIOLOGICAL EXTRAPOLATION FOR EUROPE AND ECONOMIC CONSIDERATIONS

    Nov 1, 2006, 00:00

  • PCN64 DIFFERENTIAL ITEM FUNCTIONING USING RASCH ANALYSIS

    Nov 1, 2006, 00:00

  • PGI8 COST-EFFECTIVENESS ANALYSIS OF ROTAVIRUS VACCINATION PROGRAMME IN THE UK

    Nov 1, 2006, 00:00

  • PAA2 EFFECT OF SUBLINGUAL IMMUNOTHERAPY (SLIT) ON DIRECT MEDICAL COSTS FOR PATIENTS WITH ALLERGIC RHINITIS AND ASTHMA- RESULTS FROM THE SIMAP DATABASE STUDY

    Nov 1, 2006, 00:00

  • PUK11 COST UTILITY ANALYSIS OF ERYTHROPOIETIN THERAPY IN THE MINISTRY OF HEALTH DIALYSIS PROGRAMME

    Nov 1, 2006, 00:00

  • PND11 MODELING LONG-TERM “REAL WORLD” OUTCOMES OF DISEASE-MODIFYING THERAPY IN RELAPSING-REMITTING ONSET MULTIPLE SCLEROSIS

    Nov 1, 2006, 00:00

  • PDB3 THE COST-BENEFIT OF KERRABOOT USE IN DIABETIC FOOT ULCER MANAGEMENT

    Nov 1, 2006, 00:00

  • RS3 THE COST-EFFECTIVENESS OF TIOTROPIUM VERSUS IPRATROPIUM IN A US VETERANS POPULATION DIAGNOSED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    Nov 1, 2006, 00:00

  • PSK8 CONVERGENT VALIDITY AND SENSITIVITY TO CHANGE OF THE GENERIC INSTRUMENT EQ-5D AND THE DISEASESPECIFIC DLQI IN ATOPIC DERMATITIS

    Nov 1, 2006, 00:00

  • PHP12 WASTAGE OF MEDICINES IN PORTUGAL

    Nov 1, 2006, 00:00

  • PSK1 EFFICACY OF BIOLOGICAL THERAPIES IN THE TREATMENT OF PSORIASIS- A META-ANALYSIS

    Nov 1, 2006, 00:00

  • IH3 FEASIBILITY AND PRIMARY VALIDITY OF A GERMAN EQ-5D CHILDREN'S VERSION

    Nov 1, 2006, 00:00

  • PHP10 POTENTIAL IMPACT OF HOSPITAL DISCHARGE PRESCRIPTIONS ON COMMUNITY PRESCRIBING-AN IRISH PERSPECTIVE

    Nov 1, 2006, 00:00

  • PDB23 THE COST-EFFECTIVENESS OF INHALED INSULIN IN SWEDEN

    Nov 1, 2006, 00:00

  • PUK9 COST OF ILLNESS IN ITALIAN WOMEN WITH LUTS FOLLOWED AT UROLOGY CENTRES- THE FLOW STUDY

    Nov 1, 2006, 00:00

  • PEY24 METRIC PROPERTIES OF THE MACDQOL IN FRENCH, GERMAN, ITALIAN, AND AMERICAN POPULATIONS- AN INDIVIDUALISED QOL INSTRUMENT SPECIFIC TO MACULAR DISEASE (MD)

    Nov 1, 2006, 00:00

  • PMH20 TREATMENT PATHWAYS AND COST ASSESSMENT OF SCHIZOPHRENIA IN GREECE- A PRIMARY ANALYSIS

    Nov 1, 2006, 00:00

  • PDB43 EFFECT OF INSULIN GLARGINE AND NPH ON QUALITY OF LIFE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

    Nov 1, 2006, 00:00

  • PDB40 HEALTH-RELATED QUALITY OF LIFE OF TYPE 2 DIABETICS IN GERMAN PRIMARY CARE- RESULTS OF THE DETECT STUDY

    Nov 1, 2006, 00:00

  • PEY22 MEDICATION ADHERENCE AND HEALTH CARE COSTS WITH INTRODUCTION OF LATANOPROST THERAPY FOR GLAUCOMA IN A MEDICARE MANAGED CARE POPULATION

    Nov 1, 2006, 00:00

  • PIN17 THE COST-EFFECTIVENESS OF A MENINGOCOCCAL SEROGROUP C CONJUGATE VACCINE IN GERMANY

    Nov 1, 2006, 00:00

  • PSM1 THE HIGH COST OF CIGARETTE SMOKING IN GERMANY IN 2003

    Nov 1, 2006, 00:00

  • PSK11 CARE GIVERS' WILLINGNESS TO PAY FOR DIFFERENT CHARACTERISTICS OF THE ATOPIC DERMATITIS TREATMENT

    Nov 1, 2006, 00:00

  • PDB35 COST-EFFECTIVENESS OF INHALED INSULIN IN PATIENTS WITH DIABETES UNCONTROLLED ON THEIR CURRENT THERAPY- THE UK BASE CASE SUBMITTED TO THE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE (NICE)

    Nov 1, 2006, 00:00

  • PCV43 COST ANALYSIS OF TREATMENT WITH NESIRITIDE FOR ACUTE DECOMPENSATED HEART FAILURE IN A BRAZILIAN SETTING

    Nov 1, 2006, 00:00

  • PRS5 COSTS OF COPD EXACERBATIONS IN POLAND (RESULTS OF THE PILOT STUDY)

    Nov 1, 2006, 00:00

  • PCN21 RETROSPECTIVE COMPARATIVE PHARMACOECONOMIC ANALYSIS OF VARIOUS TREATMENT SCHEMES IN PATIENTS WITH ADVANCED HODGKIN'S DISEASE

    Nov 1, 2006, 00:00

  • PCN12 COST EFFECTIVENESS OF ERLOTINIB IN THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER (NSCLC) IN POLAND

    Nov 1, 2006, 00:00

  • PHP35 TELEMEDICINE IN THE U.S. MEDICARE PROGRAM- 2007 REIMBURSEMENT IMPLICATIONS

    Nov 1, 2006, 00:00

  • PCV39 PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN PATIENTS WITH TYPE II DIABETES A COST-MINIMIZATION ANALYSIS

    Nov 1, 2006, 00:00

  • PUK7 ECONOMIC EVALUATION OF TRANSURETHRAL NEEDLE ABLATION (PROSTIVA®) VS.TRANSURETHRAL RESECTION OF THE PROSTATE (TURP) IN BENIGN PROSTATIC HYPERPLASIA (BPH) IN THE SPANISH SETTING

    Nov 1, 2006, 00:00

  • PMC10 ESTIMATING UTILITY VALUES FOR HEALTH STATUS USING THE SPANISH VERSION OF THE SF-36. IS IT WORTHY TO CALCULATE WEIGHT VALUES FOR UTILITY MEASURES?

    Nov 1, 2006, 00:00

  • PIN10 COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) FOR THE TREATMENT OF CHRONIC HEPATITIS B IN ITALY

    Nov 1, 2006, 00:00

  • RS2 TREATMENT WITH INHALED CORTICOSTEROIDS IN ASTHMA TOO OFTEN DISCONTINUED

    Nov 1, 2006, 00:00

  • PSK10 OVERCOMING DIFFERENTIAL ITEM FUNCTIONING ASSOCIATED WITH MEASURING PATIENT REPORTED OUTCOMES IN MULTINATIONAL CLINICAL TRIALS

    Nov 1, 2006, 00:00

  • PMH38 A MODEL TO ASSESS THE COST-EFFECTIVENESS OF NEW TREATMENTS FOR DEPRESSION

    Nov 1, 2006, 00:00

  • PMH18 DIRECT COST OF DEPRESSION–ANALYSIS OF A GERMAN CLAIMS DATABASE

    Nov 1, 2006, 00:00

  • PIH22 LINGUISTIC VALIDATION OF THE MENSTRUAL DISTRESS QUESTIONNAIRE (MDQ) IN AN INTERNATIONAL STUDY FOR A NEW COMBINED ORAL CONTRACEPTIVE PILL

    Nov 1, 2006, 00:00

  • PAA12 THE EFFECT OF SWITCHING ON ADHERENCE TO DIFFERENT TYPES OF ASTHMA TREATMENT

    Nov 1, 2006, 00:00

  • PHM14 PATIENT PREFERENCE AND WILLINGNESS-TO-PAY FOR ANTICOAGULANT TREATMENT OPTIONS IN PATIENTS RECEIVING ORAL ANTICOAGULANT TREATMENT (OAT)- A DISCRETE CHOICE EXERCISE

    Nov 1, 2006, 00:00

  • PDB44 EXPLORING DIFFERENCES IN PATIENT VERSUS PUBLIC PREFERENCES IN HEALTH UTILITIES-A QUALITATIVE STUDY

    Nov 1, 2006, 00:00

  • PMH28 THE MANAGEMENT OF SCHIZOPHRENIA THROUGH CLINICAL PATHWAYS

    Nov 1, 2006, 00:00

  • IN1 BUDGETARY IMPACT OF PNEUMOCOCCAL CONJUGATE VACCINATION OF NEWBORNS IN THE PERSPECTIVE OF THE REGIONAL HEALTH CARE SYSTEM OF LOMBARDY

    Nov 1, 2006, 00:00

  • PCV33 COST-EFFECTIVENESS MODEL TO EVALUATE MANAGED VENTRICULAR PACING (MVP) IMPLANTED IN A SPANISH AMBULATORY SURGERY PROGRAM

    Nov 1, 2006, 00:00

  • PUK4 AN ECONOMIC EVALUATION OF DE NOVO RENAL TRANSPLANT RECIPIENTS USING BRANDED (B-CSA) VS. NON-BRANDED CYCLOSPORINE MODIFIED (NB-CSA)

    Nov 1, 2006, 00:00

  • MC7 TRANSLATION AND VALIDATION OF NEW LANGUAGE VERSIONS OF THE ANKYLOSING SPONDYLITIS QUALITY OF LIFE (ASQOL) QUESTIONNAIRE

    Nov 1, 2006, 00:00

  • PCN2 INCIDENCE AND SURVIVAL STUDY BY STAGE AND ESTIMATED PREVALENCE OF RENAL PARENCHYMA CANCER IN FRANCE

    Nov 1, 2006, 00:00

  • POS4 COMPARING THE COST-EFFECTIVENESS OF RHBMP-2 IN THE TREATMENT OF OPEN TIBIA FRACTURES IN GERMANY, FRANCE, AND UK

    Nov 1, 2006, 00:00

  • PCV37 COST-EFFECTIVENESS OF LONG-TERM TREATMENT OF HYPERTENSION WITH IRBESARTAN VS. LOSARTAN OR NO TREATMENT IN DENMARK

    Nov 1, 2006, 00:00

  • PGI10 COST-EFFECTIVENESS OF ESOMEPRAZOLE VERSUS GENERIC OMEPRAZOLE IN THE ACUTE TREATMENT OF REFLUX ESOPHAGITIS IN GERMANY

    Nov 1, 2006, 00:00

  • PAR3 AN ECONOMIC EVALUATION OF THE USE OF EXOGEN FOR FRESH AND NON-UNION FRACTURES OF THE TIBIA IN THE UK

    Nov 1, 2006, 00:00

  • PRS18 MEASURING DISEASE-SPECIFIC UTILITIES FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE HEALTH- AND EXACERBATION PROFILES

    Nov 1, 2006, 00:00

  • PEY15 LATANOPROST VERSUS TIMOLOL MONOTHERAPY FOR THE TREATMENT OF GLAUCOMA-A COST-EFFECTIVNESS ANALYSIS IN SCANDINAVIA AND THE UK USING A DECISION-ANALYTIC HEALTH ECONOMIC MODEL

    Nov 1, 2006, 00:00

  • PCN43 COST-EFFECTIVENESS OF CETUXIMAB (ERBITUX®) IN COMBINATION WITH RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN THE TREATMENT OF LOCALLY ADVANCED HEAD AND NECK CANCER IN FRANCE

    Nov 1, 2006, 00:00

  • PCV63 DEVELOPING HOSPICE DRUG FORMULARIES USING MULTIATTRIBUTE UTILITY THEORY (MAUT) METHOD AND THE EVALUATION OF THEIR ECONOMIC IMPACT

    Nov 1, 2006, 00:00

  • PCN70 RELIABILITY AND VALIDITY OF HEALTH UTILITIES INDEX (HUI) SCORES FOR SURVIVORS OF BRAIN TUMORS IN CHILDHOOD- AGREEMENT BETWEEN PATIENTS AND PARENTS

    Nov 1, 2006, 00:00

  • PUK17 USE OF SIMULATION TO CAPTURE THE MULTIFACTORIAL ASPECTS OF RENAL DISEASE

    Nov 1, 2006, 00:00

  • PCN7 IMPACT OF CHANGES IN THE FINANCING OF THE HEALTH SERVICES ON COSTS STRUCTURE ON THE EXAMPLE OF CHEMOTHERAPY OF ADVANCED OVARIAN CANCER

    Nov 1, 2006, 00:00

  • PMH46 ASSESSING THE CROSS-CULTURAL COMPARABILITY OF THE CENTRE FOR EPIDEMIOLOGIC STUDIES DEPRESSION SCALE (CES-D)

    Nov 1, 2006, 00:00

  • PCV79 CLASSIFYING PATIENTS WITH DYSLIPIDEMIA- A LATENT CLASS ANALYSIS

    Nov 1, 2006, 00:00

  • PDB49 TREATMENT SATISFACTION WITH INSULIN GLARGINE AND INSULIN GLULISINE IN DIABETES MELLITUS-EVALUATED IN AN OBSERVATIONAL STUDY IN GERMANY

    Nov 1, 2006, 00:00

  • PST1 BUDGETARY IMPACT ANALYSIS OF RECOMBINANT ACTIVATED FACTOR VII IN THE TREATMENT OF INTRACEREBRAL HEMORRHAGE- A US HEALTH PLAN PERSPECTIVE

    Nov 1, 2006, 00:00

  • PND15 RELAPSING-REMITTING MULTIPLE SCLEROSIS (RR-MS) PATIENTS' VALUATION OF MS TREATMENT BENEFITS

    Nov 1, 2006, 00:00

  • PIN11 COST-EFFECTIVENESS OF OSELTAMIVIR FOR THE TREATMENT OF INFLUENZA IN ADULTS AND CHILDREN IN FINLAND

    Nov 1, 2006, 00:00

  • ES4 SYSTEMATIC REVIEW OF BUDGET IMPACT ANALYSES

    Nov 1, 2006, 00:00

  • PMH22 REHOSPITALIZATION RATES IN SCHIZOPHRENIA- COMPREHENSIVE LITERATURE REVIEW

    Nov 1, 2006, 00:00

  • PDB21 ECONOMIC EVALUATION OF INITIATING INSULIN DETEMIR AMONG TYPE 2 DIABETES PATIENTS RECEIVING ORAL MEDICATION

    Nov 1, 2006, 00:00

  • PEY8 WHEN IS IT COST-EFFECTIVE TO TREAT OCULAR HYPERTENSION? RESULTS OF A DECISION-ANALYTIC HEALTH ECONOMIC MODEL

    Nov 1, 2006, 00:00

  • PHP27 THE ANALYSIS OF TEMPORARY WORK DISABILITY FOR THE PERIOD OF OVER 30 DAYS IN THE REPUBLIC OF SERBIA

    Nov 1, 2006, 00:00

  • MC5 HUMANISTIC BURDEN AND HEALTH RESOURCE UTILIZATION AMONG NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (AMD) PATIENTS- RESULTS FOR GERMANY FROM A MULTI-COUNTRY CROSSSECTIONAL STUDY

    Nov 1, 2006, 00:00

  • PCV91 PSICOMETRIC PROPERTIES OF THE TREATMENT SATISFACTION WITH MEDICINES QUESTIONNAIRE (SATMED-Q) IN HIPERTENSIVE PATIENTS

    Nov 1, 2006, 00:00

  • PMH37 BURDEN OF ILLNESS OF PATIENTS WITH ANXIETY IN THE UK

    Nov 1, 2006, 00:00

  • PIN31 HEALTH RELATED QUALITY OF LIFE IN CHRONIC HEPATITIS B PATIENTS

    Nov 1, 2006, 00:00

  • HP3 THE ROLE OF GENERAL PRACTITIONERS IN THE INITIAL MANAGEMENT OF WOMEN WITH URINARY INCONTINENCE IN FRANCE, GERMANY, SPAIN AND THE UK

    Nov 1, 2006, 00:00

  • PCV13 EFFECT OF ABSOLUTE REDUCTION IN LDL CHOLESTEROL ON CARDIOVASCULAR EVENTS- DOES FINAL LDL CHOLESTEROL ACHEIVED MATTER?

    Nov 1, 2006, 00:00

  • PPN3 SAFETY OF INTRAVENOUS FORMULATIONS OF METAMIZOLE, KETOPROFEN AND PARACETAMOL—ANALYSIS OF DATA FROM WHO PROGRAMME FOR INTERNATIONAL DRUG MONITORING

    Nov 1, 2006, 00:00

  • POS3 KAPLAN-MEIER SURVIVAL ANALYSIS OF PATIENTS WITH MEDIAL AND LATERAL FEMORAL NECK FRACTURE OVER 60

    Nov 1, 2006, 00:00

  • PCV45 COST OF CHRONIC VENOUS INSUFFICIENCY (CVI) IN POLAND

    Nov 1, 2006, 00:00

  • PGI5 GASTROINTESTINAL MEDICATION USE AND COSTS IN HEART TRANSPLANT RECIPIENTS RECEIVING MYCOPHENOLATE MOFETIL

    Nov 1, 2006, 00:00

  • PCN54 ESTIMATING THE CLINICAL BENEFITS OF HPV-16/18 VACCINATION- CHALLENGES OF MODELING PREDICTED CASES OF CERVICAL CANCER IN POLAND AND MEXICO, TWO COUNTRIES WITH DIFFERING DEGREES OF CERVICAL DISEASE AND POPULATION STABILITY

    Nov 1, 2006, 00:00

  • PDB25 COST OF INPATIENT AND OUTPATIENT CARE OF SWEDISH PATIENTS WITH DIABETES MELLITUS

    Nov 1, 2006, 00:00

  • PCV22 COST IMPACT OF DIAGNOSTIC IMAGING FOR LOWER EXTREMITY PERIPHERAL VASCULAR DISEASE (PVD)

    Nov 1, 2006, 00:00

  • PIN12 COST MINIMALISATION ANALYSIS OF AVERAGE ACUTE HOSPITAL INFECTIONS TREATMENT WITH TARGOCID (TEICOPLANIN) OR VANCOMYCINE FROM SERVICEPROVIDER PERSPECTIVE IN POLAND

    Nov 1, 2006, 00:00

  • PHM8 INDIRECT COSTS OF BETA THALASSEMIA MAJOR- RESULTS FROM THE ITACA STUDY

    Nov 1, 2006, 00:00

  • PCN58 PRESCRIPTION MEDICATION COSTS TO PROSTATE CANCER PATIENTS- SURVEY RESPONSES COMPARED TO AN ADMINISTRATIVE REGISTER

    Nov 1, 2006, 00:00

  • PHP32 PATIENT SATISFACTION WITH THE PHARMACY FIRST MINOR AILMENTS SCHEME

    Nov 1, 2006, 00:00

  • PIN20 COSTS AND OUTCOMES OF NOSOCOMIAL PNEUMONIA IN A SAMPLE OF BELGIAN HOSPITALS

    Nov 1, 2006, 00:00

  • PCV51 ECONOMIC EVALUATION OF DIAGNOSTIC STRATEGIES IN PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE (CAD) IN THE UK

    Nov 1, 2006, 00:00

  • PHP40 COST-EFFECTIVENESS STUDY OF ADJUSTED CLINICAL GROUPS TO ASSESS THE ABILITY OF SPANISH PRIMARY CARE TEAMS TO BRING ISSUES TO RESOLUTION

    Nov 1, 2006, 00:00

  • PHP9 USE OF ANTIBIOTICS AT CLINICAL CENTRE OF MONTENEGRO

    Nov 1, 2006, 00:00

  • PHP15 IMPACT OF A DRUG POLICY ON AVAILABILITY AND DRUG COST CONTAINMENT IN A TERTIARY CARE HOSPITAL- 10 YEARS OF EXPERIENCE

    Nov 1, 2006, 00:00

  • PMH36 SIX-MONTH FOLLOW-UP FROM THE ELECTRONICSCHIZOPHRENIA ADHERENCE TREATMENT REGISTRY (ESTAR) OF PATIENTS IN SPAIN WHO WERE INITIATED TO RISPERIDONE LONG-ACTING INJECTION (RLAI)

    Nov 1, 2006, 00:00

  • ES5 RIMONABANT FOR THE TREATMENT OF OVERWEIGHT AND OBESE INDIVIDUALS AT INCREASED CARDIOMETABOLIC RISK-AN ECONOMIC EVALUATION USING DISCRETE EVENT SIMULATION

    Nov 1, 2006, 00:00

  • CV7 RESOURCE UTILIZATION AND COSTS FOLLOWING HOSPITAL INPATIENT ADMISSION FOR CONGESTIVE HEART FAILURE

    Nov 1, 2006, 00:00

  • POS12 THE DIFFUSION OF NEW DRUG IN TAIWAN MEDICAL CARE UNDER NATIONAL HEALTH INSURANCE- THE CASE OF COX2

    Nov 1, 2006, 00:00

  • PST2 STROKE PATIENT RESOURCE USE AND CAREGIVER BURDEN OUTCOMES BY SEVERITY (RECOVERY) STUDY- METHODS AND PRELIMINARY GERMAN RESULTS

    Nov 1, 2006, 00:00

  • PCN26 PHARMACOECONOMIC ANALYSIS IN SPAIN OF THERAPY WITH ERLOTINIB, DOCETAXEL, PEMETREXED OR BEST SUPPORTIVE CARE IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER WHO HAVE FAILED PREVIOUS CHEMOTHERAPY REGIMENS

    Nov 1, 2006, 00:00

  • PIH20 CONJOINT-ANALYSIS QALYS FOR ACUTE CONDITIONS

    Nov 1, 2006, 00:00

  • PCV71 PHARMACOECONOMIC ANALYSIS OF TREATMENT OF HYPERTENSION IN CLINICAL CENTER OF SERBIAPHARMACY AND MEDICAL SUPPLY

    Nov 1, 2006, 00:00

  • PGI9 FIBRIN-COATED COLLAGEN FLEECE PATCHES OR FIBRIN GLUE? CLINICAL OUTCOMES FOLLOWING LIVER RESECTION SHOW NO DIFFERENCES

    Nov 1, 2006, 00:00

  • PCN60 ASSESSMENT OF THE COMPUTATIONAL INTELLIGENCE BASED MODELS USEFULNESS FOR PHARMACOECONOMICS NEEDS

    Nov 1, 2006, 00:00

  • MC6 HOW DO THE SCORES OF GENERIC HRQOL INSTRUMENTS REFLECT THE DIRECT TTO VALUATIONS OF OWN HEALTH BY GENERAL POPULATION?

    Nov 1, 2006, 00:00

  • PHP3 PRICING AND REIMBURSEMENT OF ORPHAN DRUGS IN ITALY

    Nov 1, 2006, 00:00

  • PGI20 THE ASSOCIATION BETWEEN WORK PRODUCTIVITY AND RESPONSE TO PROTON PUMP INHIBITOR THERAPY IN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE

    Nov 1, 2006, 00:00

  • ES8 TREATMENT COSTS OF DIFFERENT PHASES IN BREAST CANCER (BC) IN HUNGARY

    Nov 1, 2006, 00:00

  • PCN3 EPIDEMIOLOGIC, HUMANISTIC AND ECONOMIC BURDEN OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)

    Nov 1, 2006, 00:00

  • PCV15 ANALYSIS OF PRESCRIBING PATTERNS OF ANTIHYPERTENSIVE AGENTS (AA) BEFORE AND AFTER PUBLICATION OF THE ANTIHYPERTENSIVE AND LIPIDLOWERING TREATMENT TO PREVENT HEART ATTACK TRIAL (ALLHAT)

    Nov 1, 2006, 00:00

  • PR2 ESTIMATING UTILITY VALUES FOR HEALTH STATUS USING THE SPANISH VERSION OF THE SF-36. DATA OF VALIDITY OF THE SF-6D VS EQ-5D IN SPAIN

    Nov 1, 2006, 00:00

  • PIN27 ECONOMIC MODELLING TO DETERMINE THE COSTEFFECTIVENESS OF TREATMENT OF PATIENTS WITH HISTOLOGICALLY MILD CHRONIC HEPATITIS C WITH PEGYLATED INTERFERON ALPHA-2B PLUS RIBAVIRIN

    Nov 1, 2006, 00:00

  • PMH30 DIFFUSION OF NEWLY-APPROVED GENERIC DRUG PRODUCT USE WITHIN A STATE EMPLOYEE PRESCRIPTION DRUG PROGRAM- A COMPARISON OF MAIL ORDER VERSUS RETAIL PHARMACY CLAIMS

    Nov 1, 2006, 00:00

  • PIN32 VALIDATION OF THE PATIENTS' ATTITUDES AND PERCEPTIONS TOWARDS HAART QUESTIONNAIRE

    Nov 1, 2006, 00:00

  • POB4 USING CLAIMS DATA TO UNDERSTAND THE COSTS OF DIFFERENT HEALTH STATES FOR PATIENTS WITH CARDIOMETABOLIC RISK

    Nov 1, 2006, 00:00

  • CV4 ASSESSING COST-EFFECTIVENESS BEFORE MARKETING- A CASE-STUDY OF RIMONABANT FOR REDUCTION OF CARDIOMETABOLIC RISK IN PATIENTS WITH DYSLIPIDEMIA IN THE UK

    Nov 1, 2006, 00:00

  • PRS8 RISK OF HOSPITALIZATIONS AND/OR EMERGENCY DEPARTMENT VISITS FOR MEDICAID PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)- COMPARISON OF CONTROLLERS

    Nov 1, 2006, 00:00

  • PDB29 COMPARING THE DEVELOPMENT OF A GERMAN DIABETES POPULATION WITH RESPECT TO LONGTERM OUTCOMES USING DATA FROM THE DETECT STUDY AND THE EAGLE DIABETES SIMULATION MODEL

    Nov 1, 2006, 00:00

  • PCV67 PROJECTED COST SAVINGS TO THIRD PARTY PAYERS FOR THE YEAR FOLLOWING GENERIC SIMVASTATIN AVAILABILITY IN USA

    Nov 1, 2006, 00:00

  • PCV5 DRUG-ELUTING STENT USE IS ASSOCIATED WITH SIGNIFICANT IMPROVEMENTS IN LONG-TERM CLINICAL OUTCOMES

    Nov 1, 2006, 00:00

  • PHP17 EFFICIENCY OF RHEUMATOLOGY HOSPITAL CARE- CHANGES IN THE AVERAGE LENGTH OF STAY IN RHEUMATOLOGY DEPARTMENTS IN HUNGARY

    Nov 1, 2006, 00:00

  • PDB22 EVALUATING THE LONG-TERM HEALTH OUTCOMES AND ECONOMICS OF INITIATING BIPHASIC ANALOG INSULIN COMPARED TO OPTIMIZED ORAL THERAPY ALONE

    Nov 1, 2006, 00:00

  • PCV66 THE VALUE OF MYOCARDIAL PERFUSION SCINTIGRAPHY (MPS) IN CORONARY ARTERY DISEASE (CAD)-A REVIEW OF THE ECONOMIC LITERATURE SUBMITTED TO THE UK NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE (NICE)

    Nov 1, 2006, 00:00
  • «
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156 (current)
  • 157
  • 158
  • 159
  • 160
  • »